Part II: Public Payers in the U.S. & Key International Markets

October 3, 2019 4:00 PM - 6:30 PM

MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139

This event, Part II in a three part series that will explore the value of health, will focus on Medicare and Medicaid in the U.S., existing access and reimbursement issues for innovative therapies and cures, proposed changes to those programs that could impact access and reimbursement, and barriers that exist to innovative payment models. The event will also consider those key international models of assessing value and determining access, how the global landscape is shifting, what the U.S. may be able to learn from them, and highlight emerging markets like China that are moving toward the realm of “must consider” when developing an international strategy. Speakers will share lessons learned and case studies around:

  • How Louisiana Medicaid cured its Hepatitis C population through an innovative payment model with Gilead Sciences 
  • How Biogen and Alnylam approached approvals abroad; lessons learned for navigating health technology assessment (HTA) consolidation in Europe
  • Why a US biotech partnered with a Chinese company to reach the large patient populations in China

We believe this issue is especially timely. We’re at an inflection point, with science that’s been tested for decades finally becoming a reality for patients and a payer system that has not caught up with this level of innovation. Myriad factors are combining to alter the status quo – with policymakers demanding action, and healthcare stakeholders agreeing that we must come up with real solutions. If we don’t come together and address the value equation as an industry and ensure patient access to all new therapies, government or other stakeholders will – and they will likely get it wrong. Download the Part II whitepaper

Drinks and appetizers will be provided. If you're not a MassBio member but are interested in attending, please email

Senior Director, Policy, Gilead Sciences
James Class leads IP, Value and Innovation policy for Gilead from its Washington, DC office. In this role, he manages cross-functional company efforts on Intellectual Property and Trade Policy, as well as Value Frameworks. James worked for almost a decade at PhRMA with responsibility for diverse public policy issues at the state, federal and international levels. He then spent seven years at Merck, where he held roles in Corporate Strategy, Regional and Country Commercial Operations and Global Public Policy in the US, Russia and Switzerland. James holds a PhD with distinction in Russian intellectual history from Georgetown University, has published original research in peer-reviewed journals, and has lived and traveled extensively throughout the world, promoting policies on science-based biologics regulation, pricing, and intellectual property among others. He also established the Board of the Partnership for Safe Medicines and launched the first direct-to-patient counterfeit drug alert system. He has participated in numerous stakeholder initiatives, including Interpol, WHO, and the USPTO Training Academy, as well as in trade associations like BIO, PhRMA, and IFPMA.